Glucagon-Like Peptide-1 Agonist (GLP-1)

DRUG3 trials

Sponsors

Janssen Research & Development, LLC, Johns Hopkins University, Ohio State University

Conditions

Alcohol Use DisorderDiabetes (DM)Diabetes Mellitus, Type 2Obesity & Overweight

Phase 2

Combination Therapy for Alcohol Use Disorder

Not yet recruitingNCT07249554

Johns Hopkins UniversityAlcohol Use Disorder

Start: 2026-09-01End: 2028-09-01Target: 45Updated: 2026-07-13

Unknown Phase

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

CompletedNCT03249506

Janssen Research & Development, LLCDiabetes Mellitus, Type 2

Start: 2016-05-12End: 2017-11-01Updated: 2017-11-21

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

RecruitingNCT07702461

Ohio State UniversityDiabetes (DM), Obesity & Overweight

Start: 2026-06-12End: 2027-01-01Target: 300Updated: 2026-07-14